Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURATION-6: Exenatide Once Weekly vs Liraglutide in T2DM
NCT01029886Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2010
- Primary completion
- Jan 2011
- Modality
- Peptides
- Countries
- 21
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Jan 2010; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01029886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01029886.